<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34921561</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4604</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical pharmacology</Title>
          <ISOAbbreviation>J Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Different Kinetics of Activated Clotting Time Among Uninterrupted Oral Anticoagulants During Catheter Ablation Procedure.</ArticleTitle>
        <Pagination>
          <StartPage>792</StartPage>
          <EndPage>800</EndPage>
          <MedlinePgn>792-800</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcph.2018</ELocationID>
        <Abstract>
          <AbstractText>Activated clotting time (ACT) kinetics under uninterrupted oral anticoagulants (OACs) has not been fully evaluated. The present study is sought to validate ACT kinetics including stability under uninterrupted use of OACs during an ablation procedure in daily clinical practice. We prospectively enrolled consecutive 554 patients with atrial fibrillation who underwent catheter ablation procedure under uninterrupted OACs. We evaluated ACT kinetics at an interval of 15 minutes during the procedure and periprocedural complications among 5 OACs (dabigatran [N = 46], rivaroxaban [N = 125], apixaban [N = 129], edoxaban [N = 184], and warfarin [N = 70]). Compared with the dabigatran group, time to achieve target ACT was significantly longer in the rivaroxaban and apixaban groups, but not in the edoxaban and warfarin groups (8.7 vs 11.7 minutes, P &lt; .001; 13.3 minutes, P &lt; .001; 8.8 minutes, P = .64; 10.3 minutes, P = .19, respectively). Heparin dose to achieve target ACT was comparable except for the warfarin group, whereas, compared with the dabigatran group, time in therapeutic range of ACT within the first hour was comparable in the rivaroxaban and apixaban group but significantly lower in the edoxaban and warfarin groups (73.7 % vs 63.0%, P = .06; 67.0 %, P = .16; 59.2 %, P = .001; 58.2%, P = .004, respectively). In multiple regression analysis, low body weight, rivaroxaban, apixaban, and morning session had significant associations with time and heparin dose to achieve target ACT, and there were positive associations of dabigatran and apixaban with time in therapeutic range of ACT within the first hour. The incidence of periprocedural complications did not significantly differ among the 5 groups. Under uninterrupted OAC use in daily clinical practice, dabigatran showed faster achievement of target ACT and higher stability of ACT than other OACs.</AbstractText>
          <CopyrightInformation>Â© 2021, The American College of Clinical Pharmacology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kawaji</LastName>
            <ForeName>Tetsuma</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-9929-902X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morimoto</LastName>
            <ForeName>Takeshi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aizawa</LastName>
            <ForeName>Takanori</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hojo</LastName>
            <ForeName>Shun</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kushiyama</LastName>
            <ForeName>Akihiro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yaku</LastName>
            <ForeName>Hidenori</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakatsuma</LastName>
            <ForeName>Kenji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaneda</LastName>
            <ForeName>Kazuhisa</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kato</LastName>
            <ForeName>Masashi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yokomatsu</LastName>
            <ForeName>Takafumi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miki</LastName>
            <ForeName>Shinji</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kimura</LastName>
            <ForeName>Takeshi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Clin Pharmacol</MedlineTA>
        <NlmUniqueID>0366372</NlmUniqueID>
        <ISSNLinking>0091-2700</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9005-49-6</RegistryNumber>
          <NameOfSubstance UI="D006493">Heparin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9NDF7JZ4M3</RegistryNumber>
          <NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I0VM4M70GC</RegistryNumber>
          <NameOfSubstance UI="D000069604">Dabigatran</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017115" MajorTopicYN="Y">Catheter Ablation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069604" MajorTopicYN="N">Dabigatran</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">activated clotting time</Keyword>
        <Keyword MajorTopicYN="Y">atrial fibrillation</Keyword>
        <Keyword MajorTopicYN="Y">catheter ablation</Keyword>
        <Keyword MajorTopicYN="Y">oral anticoagulant</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>8</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34921561</ArticleId>
        <ArticleId IdType="doi">10.1002/jcph.2018</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Calkins H, Hindricks G, Cappato R, etÂ al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20:e1-e160.</Citation>
        </Reference>
        <Reference>
          <Citation>January CT, Wann LS, Calkins H, etÂ al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125-e151.</Citation>
        </Reference>
        <Reference>
          <Citation>Martin A-C, Godier A, Narayanan K, etÂ al. Management of intraprocedural anticoagulation in patients on non-vitamin k antagonist oral anticoagulants undergoing catheter ablation for atrial fibrillation. Circulation. 2018;138:627-633.</Citation>
        </Reference>
        <Reference>
          <Citation>Nakamura K, Naito S, Sasaki T, etÂ al. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-center study on post-ablation thrombo-embolic and haemorrhagic events. Europace. 2019;21:259-267.</Citation>
        </Reference>
        <Reference>
          <Citation>Romero J, Cerrud-Rodriguez RC, Diaz JC, etÂ al. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace. 2018;20:1612-1620.</Citation>
        </Reference>
        <Reference>
          <Citation>Calkins H, Willems S, Gerstenfeld EP, etÂ al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627-1636.</Citation>
        </Reference>
        <Reference>
          <Citation>Cappato R, Marchlinski FE, Hohnloser SH, etÂ al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805-1811.</Citation>
        </Reference>
        <Reference>
          <Citation>Kirchhof P, Haeusler KG, Blank B, etÂ al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39:2942-2955.</Citation>
        </Reference>
        <Reference>
          <Citation>Hohnloser SH, Camm J, Cappato R, etÂ al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: The ELIMINATE-AF trial. Eur Heart J. 2019;40:3013-3021.</Citation>
        </Reference>
        <Reference>
          <Citation>Wazni OM, Rossillo A, Marrouche NF, etÂ al. Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: Impact of different anticoagulation regimens and importance of intracardiac echo imaging. J Cardiovasc Electrophysiol. 2005;16:576-581.</Citation>
        </Reference>
        <Reference>
          <Citation>Ren J-F, Marchlinski FE, Callans DJ. Left atrial thrombus associated with ablation for atrial fibrillation: identification with intracardiac echocardiography. J Am Coll Cardiol. 2004;43:1861-1867.</Citation>
        </Reference>
        <Reference>
          <Citation>Briceno DF, Villablanca PA, Lupercio F, etÂ al. Clinical impact of heparin kinetics during catheter ablation of atrial fibrillation: meta-analysis and meta-regression. J Cardiovasc Electrophysiol. 2016;27:683-693.</Citation>
        </Reference>
        <Reference>
          <Citation>Nagao T, Inden Y, Yanagisawa S, etÂ al. Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. Heart Rhythm. 2015;12:1972-1978.</Citation>
        </Reference>
        <Reference>
          <Citation>Harada M, Motoike Y, Nomura Y, etÂ al. Factors associated with silent cerebral events during atrial fibrillation ablation in patients on uninterrupted oral anticoagulation. J Cardiovasc Electrophysiol. 2020;31:2889-2897.</Citation>
        </Reference>
        <Reference>
          <Citation>Matsuo S, Imai E, Horio M, etÂ al. Revised equations for estimated gfr from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.</Citation>
        </Reference>
        <Reference>
          <Citation>Rosendaal FR, Cannegieter SC, van der Meer FJ, etÂ al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239.</Citation>
        </Reference>
        <Reference>
          <Citation>Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.</Citation>
        </Reference>
        <Reference>
          <Citation>Martin A-C, Kyheng M, Foissaud V, etÂ al. Activated clotting time monitoring during atrial fibrillation catheter ablation: Does the anticoagulant matter? J Clin Med. 2020;9:350.</Citation>
        </Reference>
        <Reference>
          <Citation>Nagao T, Higo S, Suzuki H, etÂ al. Prospective comparison of periprocedural coagulation markers among uninterrupted anticoagulants for atrial fibrillation ablation. Heart Rhythm. 2020;17:391-397.</Citation>
        </Reference>
        <Reference>
          <Citation>Nakamura K, Sasaki T, Take Y, etÂ al. Impact of the type of electroanatomic mapping system on the incidence of cerebral embolism after radiofrequency catheter ablation of left atrial tachycardias. Heart Rhythm. 2020;17:250-257.</Citation>
        </Reference>
        <Reference>
          <Citation>Gaita F, Caponi D, Pianelli M, etÂ al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Circulation. 2010;122:1667-1673.</Citation>
        </Reference>
        <Reference>
          <Citation>Michowitz Y, Rahkovich M, Oral H, etÂ al. Effects of sex on the incidence of cardiac tamponade after catheter ablation of atrial fibrillation: results from a worldwide survey in 34 943 atrial fibrillation ablation procedures. Circ Arrhythm Electrophysiol. 2014;7:274-280.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
